Disclosure and Conflicts of Interest Policy:
The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
Planner Disclosures:
Planner Name
|
Ineligible Company
|
Relevant Financial Relationship
|
Diana Isaacs, PhD |
(1) Abbott, Dexcom, Medtronic, Insulet, Lilly, Novo Nordisk, Cequr, Sanofi
(2) Lilly, Sanofi, Medtronic, Lifescan, Sequel |
(1) Speakers Bureau (2) Advisory Board |
Natalie Bellini, MD |
(1) Abbott, Dexcom, Medtronic, Embecta, Sanofi
(2) Medtronic, Sanofi
|
(1) Speaker / Consultant (2) Advisory Board |
Mihail Zilbermint, MD |
(1) ROM Tech
(2) Dexcom, Inc
|
(1) Stock (2) Consultant |
Viral Shah, MD |
(1) Alexion, Novo Nordisk, Enable Biosciences, Dexcom
(2) Dexcom, Genomelink and Lumosfit
|
(1) Research funding (2) Consulting |
Rifka Schulman-Rosenbaum, MD |
Sanofi |
Publication Support |
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Faculty Disclosures:
Planner Name
|
Ineligible Company
|
Relevant Financial Relationship
|
Diana Isaacs, PhD |
(1) Abbott; Dexcom; Medtronic; Insulet; Lilly; Novo Nordisk; Cequr; Sanofi
(2) Lilly; Sanofi; Medtronic; Lifescan, Sequel |
(1) Speakers Bureau (2) Advisory Board |
Natalie Bellini, MD |
(1) Abbott; Dexcom; Medtronic; Embecta; Sanofi
(2) Medtronic; Sanofi
|
(1) Speaker / Consultant (2) Advisory Board |
Mihail Zilbermint, MD |
(1) ROM Tech
(2) Dexcom, Inc.
|
(1) Stock (2) Consultant |
Viral Shah, MD |
(1) Alexion; Novo Nordisk; Enable Biosciences; Dexcom
(2) Dexcom; Genomelink; Lumosfit
|
(1) Research funding (2) Consulting |
Rifka Schulman-Rosenbaum, MD |
Sanofi |
Publication Support |
All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Reviewer Disclosures:
Reviewer Name |
Ineligible Company |
Relevant Financial Relationship |
Anupam Kotwal, MD |
Interpace Diagnostica; Immunovant
|
Consultant |
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.